Skip to content
10-K

Annual Report

TARSUS PHARMACEUTICALS, INC. TARS

0001819790-25-000011

← back to feed
Filed
Feb 25, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 19, 2025 38.38M sh
Long Term Debt FY 2024 · Dec 31, 2023 $29.82M
Cash And Equivalents FY 2024 · Dec 31, 2023 $224.95M
Current Liabilities FY 2024 · Dec 31, 2023 $36.94M
Total Liabilities FY 2024 · Dec 31, 2023 $68.5M
Current Assets FY 2024 · Dec 31, 2023 $256.13M
Total Assets FY 2024 · Dec 31, 2023 $265.49M
Shares Diluted FY 2024 · Dec 31, 2022 24.62M sh
Capex FY 2024 · Dec 31, 2022 $506K
Operating Cash Flow FY 2024 · Dec 31, 2022 −$49.03M
Eps Diluted FY 2024 · Dec 31, 2022 −$2.52
Eps Basic FY 2024 · Dec 31, 2022 −$2.52
Sga Expense FY 2024 · Dec 31, 2022 $44.95M
Rd Expense FY 2024 · Dec 31, 2022 $42.62M
Net Income FY 2024 · Dec 31, 2022 −$62.09M
Operating Income FY 2024 · Dec 31, 2022 −$62.71M
Revenue FY 2024 · Dec 31, 2022 $25.82M
Stockholders Equity FY 2024 · Dec 31, 2021 $166.73M